Loading compare…
4 funds hold both · as on Jul 2026
Comparing mutual fund co-ownership helps identify hidden asset concentration. Our reverse lookup database shows that 4 mutual funds hold active equity positions in both Advanced Enzyme Technologies and Alembic Pharmaceuticals. The scheme with the highest combined exposure is UTI - MNC Fund (UTI MF), which holds a 1.22% stake in Advanced Enzyme Technologies and a 1.01% stake in Alembic Pharmaceuticals, amounting to a combined conviction weight of 2.23%.
When multiple mutual funds in your portfolio double-up on the same stock pairs, it limits your diversification benefits. If you also hold either of these companies directly in your demat account, your aggregate exposure is amplified. This co-ownership pattern is standard among index-tracking products but represents active, concentrated strategies in equity schemes.
| Fund | Advanced wt. | Alembic wt. | Combined |
|---|---|---|---|
| UTI - MNC FundUTI MF · Sectoral / Thematic | 1.22% | 1.01% | |
| Back to IndexMotilal Oswal MF · Index Fund | 0.17% | 0.49% | |
| Back to IndexMotilal Oswal MF · Index Fund | 0.09% | 0.27% | |
| IB18-Groww Nifty Total Market Index FundGroww MF · Index Fund | 0.01% | 0.02% |
These funds hold both stocks — see how much their entire portfolios overlap.
Check overlap of top funds →“Holds both” = the fund discloses an equity position in each stock in its latest public monthly portfolio (as on Jul 2026). Weight = the position as a % of that fund's portfolio. ISIN-verified from AMC disclosures. Not investment advice.